Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Murine radiation-induced acute myeloid leukaemia (AML) is characterized by loss of one copy of chromosome 2. Previously, we positioned the critical haematopoietic-specific transcription factor PU.1 within a minimally deleted region. We now report a high frequency (>65%) of missense mutation at codon 235 in the DNA-binding Ets domain of PU.1 in murine AML. Earlier studies, outside the context of malignancy, determined that conversion of arginine 235 (R235) to any other amino-acid residue leads to ablation of DNA-binding function and loss of expression of downstream targets. We show that mutation of R235 does not lead to protein loss, and occurs specifically in those AMLs showing loss of one copy of PU.1 (P=0.001, Fisher's exact test). PU.1 mutations were not found in the coding region, UTRs or promoter of human therapy-related AMLs. Potentially regulatory elements upstream of PU.1 were located but no mutations found. In conclusion, we have identified the cause of murine radiation-induced AML and have shown that loss of one copy of PU.1, as a consequence of flanking radiation-sensitive fragile domains on chromosome 2, and subsequent R235 conversion are highly specific to this mouse model. Such a mechanism does not operate, or is extremely rare, in human AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Likewise, irradiationinduced myeloid leukemias in mice had low PU.1 levels and mutations that affected its binding to the DNA.41,42”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [42]
Citations
Cites
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130
The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene
Klemsz, M. J., McKercher, S. R., Celada, A., Van Beveren, C., & Maki, R. A. (1990) · Cell · doi:10.1016/0092-8674(90)90219-5 · Cited by 954
Transcription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 1×
“…therapy related; Ets domain; mutation PU.1 is a member of the ETS family of transcription factors and is essential for the development of both myeloid (macrophages and neutrophils) and lymphoid lineages (B- and T-lymphocytes) (Moreau-Gachelin et al., 1989; Klemsz et al., 1990; Tenen et al., 1997).”
BackgroundA breakpoint map of recurrent chromosomal rearrangements in human neoplasia
Mitelman, F., Mertens, F., & Johansson, B. (1997) · Nature Genetics · doi:10.1038/ng0497supp-417 · Cited by 698
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506
Zhang, D.-E., Hetherington, C. J., Chen, H.-M., & Tenen, D. G. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.373-381.1994 · Cited by 411
Long-range disruption of gene expression by a selectable marker cassette
Pham, C. T. N., MacIvor, D. M., Hug, B. A., Heusel, J. W., & Ley, T. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13090 · Cited by 365
Smith, L., Hohaus, S., Gonzalez, D., Dziennis, S., & Tenen, D. (1996) · Blood · doi:10.1182/blood.v88.4.1234.bloodjournal8841234 · Cited by 332
A new pattern for helix–turn–helix recognition revealed by the PU.l ETS–domain–DNA complex
Kodandapani, R., Pio, F., Ni, C.-Z., Piccialli, G., Klemsz, M., McKercher, S., Maki, R. A., & Ely, K. R. (1996) · Nature · doi:10.1038/380456a0 · Cited by 315 · cited 3×
“…factors is characterized by a highly conserved region of amino acids that form a winged (aþ b) helix-turn-helix motif, which binds DNA to facilitate promoter-specific transcriptional responses (Donaldson et al., 1994; Kodandapani et al., 1996; Pio et al., 1996; Jia et al., 1999; Figure 3).”
Background
Cited by
Transcription factors in myeloid development: balancing differentiation with transformation
Rosenbauer, F., & Tenen, D. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2024 · Cited by 606
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.
Huang, G., Zhang, P., Hirai, H., Elf, S., Yan, X., Chen, Z., Koschmieder, S., Okuno, Y., Dayaram, T., Growney, J. D., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.7 · Cited by 259
Assessing cancer risks of low-dose radiation
Mullenders, L., Atkinson, M., Paretzke, H., Sabatier, L., & Bouffler, S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2677 · Cited by 213
Mueller, B. U., Pabst, T., Fos, J., Petkovic, V., Fey, M. F., Asou, N., Buergi, U., & Tenen, D. G. (2006) · Blood · doi:10.1182/blood-2005-07-3068 · Cited by 207
Transcriptional dysregulation during myeloid transformation in AML
Pabst, T., & Mueller, B. U. (2007) · Oncogene · doi:10.1038/sj.onc.1210765 · Cited by 120
Metadata
- Authors
- Suraweera, N., Meijne, E., Moody, J., Carvajal-Carmona, L. G., Yoshida, K., Pollard, P., Fitzgibbon, J., Riches, A., van Laar, T., Huiskamp, R., Rowan, A., Tomlinson, I. P. M., & Silver, A.
- Affiliations
- Cancer Research UK (GB)
- Nuclear Research and Consultancy Group (NL)
- National Radiological Protection Board (GB)
- National Institute of Radiological Sciences (JP)
- St Bartholomew's Hospital (GB)
- University of St Andrews (GB)
- Corresponding author
- Silver, Andrew
- Venue
- Oncogene
- Published
- 2005-03-07
- Volume
- 24
- Issue
- 22
- Pages
- 3678-3683
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2062397105
- Semantic Scholar
- 5611af7e7954a33d42de06e06b159e33a8647600
- Cited by
- 60
- References
- 37
- Citations by year
- 2026: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 4 · 2015: 5 · 2014: 2 · 2013: 3 · 2012: 3
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK
- Fourth Framework Programme
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Carcinogens and Genotoxicity Assessment
- Keywords
- PU.1, ETS domain, acute myeloid leukemia, radiation-induced leukemia, therapy-related myeloid neoplasms, fragile sites, missense mutations, transcription factors, mouse model
- MeSH terms
- Proto-Oncogene Protein Spi-1, Animals, Base Sequence, Disease Models, Animal, Humans, Molecular Sequence Data, Mutation, Neoplasms, Radiation-Induced, Promoter Regions, Genetic, Proto-Oncogene Proteins, Transcription Factors, Blotting, Western, Leukemia, Myeloid, Acute, Trans-Activators, DNA Footprinting, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia. https://app.cochat.ai/papers/10.1038/sj.onc.1208422
- The paper
- Suraweera, N., Meijne, E., Moody, J., Carvajal-Carmona, L. G., Yoshida, K., Pollard, P., Fitzgibbon, J., Riches, A., van Laar, T., Huiskamp, R., Rowan, A., Tomlinson, I. P. M., & Silver, A. (2005). Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia. Oncogene. https://doi.org/10.1038/sj.onc.1208422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.